Displaying drugs 151 - 175 of 1617 in total
ST-003
ST-003 is a novel galanin receptor inhibitor being investigated for the treatment of primary sclerosing cholangitis.
Investigational
Matched Name: … ST-003 …
Matched Description: … ST-003 is a novel galanin receptor inhibitor being investigated for the treatment of primary sclerosing …
Matched Description: … ST-003 is a novel galanin receptor inhibitor being investigated for the treatment of primary sclerosing …
MRK-003
MRK-003 is a potent and selective γ-secretase inhibitor developed by Merck. It is the preclinical analog of MK-0752, a drug in clinical development.
Investigational
Matched Name: … MRK-003 …
Matched Description: … MRK-003 is a potent and selective γ-secretase inhibitor developed by Merck. ... It is the preclinical analog of [MK-0752], a drug in clinical development.[A252682] …
Matched Description: … MRK-003 is a potent and selective γ-secretase inhibitor developed by Merck. ... It is the preclinical analog of [MK-0752], a drug in clinical development.[A252682] …
MRG-003
MRG-003 is a recombinant humanized anti-human epidermal growth factor receptor monoclonal antibody conjugated to monomethyl auristatin E.
Investigational
Matched Name: … MRG-003 …
Matched Description: … MRG-003 is a recombinant humanized anti-human epidermal growth factor receptor monoclonal antibody conjugated …
Matched Description: … MRG-003 is a recombinant humanized anti-human epidermal growth factor receptor monoclonal antibody conjugated …
SOBI-003
SOBI-003 is a chemically modified variant of a recombinant human sulfamidase. It is under investigation in clinical trial NCT03811028 (A Study to Assess the Safety, Tolerability, and Efficacy of Long-term SOBI003 Treatment in Pediatric MPS IIIA Patients).
Investigational
Matched Name: … SOBI-003 …
Matched Description: … SOBI-003 is a chemically modified variant of a recombinant human sulfamidase. …
Matched Description: … SOBI-003 is a chemically modified variant of a recombinant human sulfamidase. …
iCo-007
iCo-007 (formerly known as ISIS 13650) is a second generation antisense compound being developed by iCo for the treatment of various eye diseases caused by the formation of new blood vessels (angiogenesis) such as age-related macular degeneration (AMD) and diabetic retinopathy(DR).
Investigational
Matched Name: … iCo-007 …
Matched Description: … iCo-007 (formerly known as ISIS 13650) is a second generation antisense compound being developed by iCo …
Matched Description: … iCo-007 (formerly known as ISIS 13650) is a second generation antisense compound being developed by iCo …
SIG-007
SIG-007 is a gene therapy that consists of cells that are genetically modified with a non-viral vector to express human alpha-galactosidase A. Developed by Sigilon Therapeutics, t is being investigated for the treatment of Fabry Disease.
Investigational
Matched Name: … SIG-007 …
Matched Description: … SIG-007 is a gene therapy that consists of cells that are genetically modified with a non-viral vector …
Matched Description: … SIG-007 is a gene therapy that consists of cells that are genetically modified with a non-viral vector …
NFS-02
NFS-02 is a recombinant adeno-associated virus serotype 2 containing human mitochondrial ND1 codon optimized gene (rAAV2-ND1).
Investigational
Matched Name: … NFS-02 …
Matched Description: … NFS-02 is a recombinant adeno-associated virus serotype 2 containing human mitochondrial ND1 codon optimized …
Matched Description: … NFS-02 is a recombinant adeno-associated virus serotype 2 containing human mitochondrial ND1 codon optimized …
BREN-02
BREN-02 is a recombinant human homeoprotein Engrailed 1 (rhEN1).
Investigational
Matched Name: … BREN-02 …
Matched Description: … BREN-02 is a recombinant human homeoprotein Engrailed 1 (rhEN1). …
Matched Description: … BREN-02 is a recombinant human homeoprotein Engrailed 1 (rhEN1). …
FF-10101-01
FF-10101-01 is under investigation in clinical trial NCT03194685 (Study of FF-10101-01 in Patients With Relapsed or Refractory Acute Myeloid Leukemia).
Investigational
Matched Name: … FF-10101-01 …
Matched Description: … FF-10101-01 is under investigation in clinical trial NCT03194685 (Study of FF-10101-01 in Patients With …
Matched Description: … FF-10101-01 is under investigation in clinical trial NCT03194685 (Study of FF-10101-01 in Patients With …
ADVM-053
Investigational
Matched Synonyms: … ANN 002 ... ANN-002 ... ADVM 053 …
Matched Name: … ADVM-053 …
Matched Name: … ADVM-053 …
GED-0507-34-Levo
GED-0507-34-Levo is under investigation in clinical trial NCT02808390 (Efficacy and Safety Study of Ged-0507-34-levo for Treatment of UC).
Investigational
Matched Name: … GED-0507-34-Levo …
Matched Description: … -0507-34-levo for Treatment of UC). ... GED-0507-34-Levo is under investigation in clinical trial NCT02808390 (Efficacy and Safety Study of Ged …
Matched Description: … -0507-34-levo for Treatment of UC). ... GED-0507-34-Levo is under investigation in clinical trial NCT02808390 (Efficacy and Safety Study of Ged …
FF-10501-01
FF-10501-01 is a novel, selective inosine monophosphate dehydrogenase (IMPDH) inhibitor with anticancer activity. FF-10501-01 is under investigation in clinical trial NCT03486353 (A Study of FF-10501-01 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome).
Investigational
Matched Synonyms: … FF 10501 01 …
Matched Name: … FF-10501-01 …
Matched Description: … [A257306] FF-10501-01 is under investigation in clinical trial NCT03486353 (A Study of FF-10501-01 in ... FF-10501-01 is a novel, selective inosine monophosphate dehydrogenase (IMPDH) inhibitor with anticancer …
Matched Name: … FF-10501-01 …
Matched Description: … [A257306] FF-10501-01 is under investigation in clinical trial NCT03486353 (A Study of FF-10501-01 in ... FF-10501-01 is a novel, selective inosine monophosphate dehydrogenase (IMPDH) inhibitor with anticancer …
AVR-RD-01
AVR-RD-01 is an investigational ex vivo lentiviral gene therapy developed by AVROBIO Inc. It consists of autologous CD34+ cells that transduced with Lentiviral Vector/alpha-galactosidase A (AGA) encoding for the human AGA complementary deoxyribonucleic acid (cDNA) sequence. AVR-RD-01 is being investigated for Fabry Disease.[L45963, L45968]
Investigational
Matched Name: … AVR-RD-01 …
Matched Description: … AVR-RD-01 is being investigated for Fabry Disease.[L45963, L45968] ... AVR-RD-01 is an investigational _ex vivo_ lentiviral gene therapy developed by AVROBIO Inc. …
Matched Description: … AVR-RD-01 is being investigated for Fabry Disease.[L45963, L45968] ... AVR-RD-01 is an investigational _ex vivo_ lentiviral gene therapy developed by AVROBIO Inc. …
ENA-001
Investigational
Matched Name: … ENA-001 …
Matched Salts cas: … 1380342-00-6 …
Matched Salts name: … ENA-001 hydrogen sulfate …
Matched Salts cas: … 1380342-00-6 …
Matched Salts name: … ENA-001 hydrogen sulfate …
LB-001
LB-001 is a gene editing therapy designed to incorporate a functioning version of the faulty methylmalonyl-COA mutase (MUT) gene into the genome of patients with methylmalonic acidemia.
Investigational
Matched Name: … LB-001 …
Matched Description: … LB-001 is a gene editing therapy designed to incorporate a functioning version of the faulty methylmalonyl-COA …
Matched Description: … LB-001 is a gene editing therapy designed to incorporate a functioning version of the faulty methylmalonyl-COA …
AT-001
AT-001 is under investigation in clinical trial NCT03062384 (AT-001 for Long-term Preservation of Brain Health in Aging).
Investigational
Matched Name: … AT-001 …
Matched Description: … AT-001 is under investigation in clinical trial NCT03062384 (AT-001 for Long-term Preservation of Brain …
Matched Description: … AT-001 is under investigation in clinical trial NCT03062384 (AT-001 for Long-term Preservation of Brain …
SVV-001
SVV-001 is investigated for use/treatment in cancer/tumors and lung cancer. SVV-001 is a solid. SVV-001 (Seneca Valley Virus) is a novel native picornavirus being developed as a systemically deliverable oncolytic virus for treatment of human cancers with neuroendocrine features. SVV-001 has also demonstrated cancer-killing specificity 10,000 times higher than that...
Investigational
Matched Name: … SVV-001 …
Matched Description: … SVV-001 is investigated for use/treatment in cancer/tumors and lung cancer. SVV-001 is a solid. ... SVV-001 has also demonstrated cancer-killing specificity 10,000 times higher than that of traditional ... SVV-001 (Seneca Valley Virus) is a novel native picornavirus being developed as a systemically deliverable …
Matched Description: … SVV-001 is investigated for use/treatment in cancer/tumors and lung cancer. SVV-001 is a solid. ... SVV-001 has also demonstrated cancer-killing specificity 10,000 times higher than that of traditional ... SVV-001 (Seneca Valley Virus) is a novel native picornavirus being developed as a systemically deliverable …
CYP-001
CYP-001 is a mesenchymoangioblast (MCA)-derived mesenchymal stem cell (MSC) therapy that originates from the mesoderm. When activated with fibroblast growth factor-2 (FGF-2), MCAs create colonies with specific phenotypes. These cells are then able to differentiate into bone, cartilage, and adipose tissue.
The MCA-derived MSCs can be obtained from induced pluripotent...
Investigational
Matched Name: … CYP-001 …
Matched Description: … CYP-001 is a mesenchymoangioblast (MCA)-derived mesenchymal stem cell (MSC) therapy that originates from …
Matched Description: … CYP-001 is a mesenchymoangioblast (MCA)-derived mesenchymal stem cell (MSC) therapy that originates from …
STG-001
STG-001 is under investigation in clinical trial NCT04489511 (Study of STG-001 in Subjects With Stargardt Disease).
Investigational
Matched Name: … STG-001 …
Matched Description: … STG-001 is under investigation in clinical trial NCT04489511 (Study of STG-001 in Subjects With Stargardt …
Matched Description: … STG-001 is under investigation in clinical trial NCT04489511 (Study of STG-001 in Subjects With Stargardt …
Displaying drugs 151 - 175 of 1617 in total